Q3 2016 13F Holders as of 30 Sep 2016
-
Type / Class
-
Debt / NOTE 0.750% 8/1
-
Number of holders
-
25
-
Total 13F principal, excl. options
-
244,297,000
-
Principal change
-
+1,607,000
-
Total reported value, excl. options
-
$357,451,000
-
Value change
-
-$2,220,426
-
Number of buys
-
8
-
Number of sells
-
-12
-
Price
-
$1.46
Significant Holders of LIGAND PHARMACEUTICALS INC - NOTE 0.750% 8/1 as of Q3 2016
28 filings reported holding 53220KAD0 - LIGAND PHARMACEUTICALS INC - NOTE 0.750% 8/1 as of Q3 2016.
LIGAND PHARMACEUTICALS INC - NOTE 0.750% 8/1 has 25 institutional bondholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of $244,297,000 of principal
.
Largest 10 bondholders include CITADEL ADVISORS LLC ($33,000,000 of principal), HIGHBRIDGE CAPITAL MANAGEMENT LLC ($25,000,000 of principal), CAMDEN ASSET MANAGEMENT L P /CA ($22,575,000 of principal), SUSQUEHANNA INTERNATIONAL GROUP, LLP ($20,312,000 of principal), LINDEN ADVISORS LP ($19,855,000 of principal), WOLVERINE ASSET MANAGEMENT LLC ($18,416,000 of principal), Myriad Asset Management Ltd. ($17,000,000 of principal), CQS Cayman LP ($12,000,000 of principal), Allianz Asset Management GmbH ($11,500,000 of principal), and Polygon Management Ltd. ($8,100,000 of principal).
This table shows the top 25 institutional bondholders of the company debt. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.